Total
0
Shares
ScreenPro (CSE:SCRN) completes a massive number of Covid-19 tests
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Afero has entered into a partnership with Therma Bright Inc to bring Afero's tracking technology to Therma Bright's COVID-19 rapid antigen screening test
  • AcuVid™ COVID-19 Rapid Antigen Saliva Tests will include encryption technology for tracking and reporting test results
  • An encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use
  • This partnership also paves the way for preparing the AcuVID COVID-19 Rapid Antigen Test for approval for at-home testing
  • Therma Bright is a progressive medical device technology company
  • Therma Bright Inc. (THRM) is unchanged, trading at C$0.44 per share at 11:30 am ET

Afero has partnered with Therma Bright (THRM) to bring Afero's tracking technology to Therma Bright's COVID-19 rapid antigen screening test.

The partnership aims to bring Afero's innovation, security and tracking technology to Therma Bright's 15-minute COVID-19 rapid antigen screening test.

Upon completion, the proposed agreement will offer AcuVid™ COVID-19 Rapid Antigen Saliva Tests powered by Afero, enhanced with encryption technology for tracking and reporting AcuVID test results.

This partnership also paves the way for preparing the AcuVID COVID-19 Rapid Antigen Test for approval for at-home testing. The MOU was completed and signed on April 28, 2021. Both parties expect to complete a definitive agreement and begin work on or before June 1, 2021.

Backed by the fifth largest IoT patent portfolio globally, the Afero Platform gives partners an agile development process, best-in-class security, and rapid data capture across multiple products and product generations.

Afero's mobile application supports advanced quality control features and an intuitive user experience. With the secure Afero Cloud, AcuVid™ test status is tracked and managed on a real-time basis for many millions of tests deployed around the world. And with secure Afero Integrations, millions of test results can be shared with government agencies, workplaces, entertainment venues and more.

Even with the proliferation of COVID-19 vaccines across the United States and Canada, the need for secure and reliable rapid antigen testing remains critical to help in slowing the spread of the original COVID19 virus, along with a growing list of variants.

The Afero encrypted QR Code solution will be embedded on each Acuvid Rapid Antigen Test for both enterprise and consumer use. Therma Bright will be able to use this tracking technology for quality assurance and logistics tracking as well as reporting results in a safe, secure manner first for point-of-care facilities, and then for at-home use.

"Our AcuVid COVID-19 Rapid Antigen Test, powered by Afero, will provide users our "Brighter Experience" - a complete end-to-end solution to ensure product tracking, quality control and test validation data are all cryptographically captured and secured to protect individual privacy for every test taken," explained Rob Fia, CEO of Therma Bright.

"By integrating Afero's Secure QR Code technology, each AcuVid test deployed will be validated for its efficacy and confirmed on the Afero-powered mobile application. All data captured will be securely stored in the Afero Cloud. If accepted by the end user, their test results can then be transmitted to their personal healthcare practitioner, and/or to their mobile health wallet for ease of use and test verification."

"The opportunity to work with Therma Bright to help mitigate community spread of COVID-19 is a critical step in the growth of our intelligent edge technology," said Joe Britt, Afero co-founder and CEO.

"Therma Bright's AcuVid COVID-19 Rapid Antigen Test, powered by Afero, is measurable progress towards enabling everyone on the planet to be able to take a secure, simple, reliable saliva-based test. Afero's expertise in user validation, security, data management and data analytics serve as a critical platform for deploying a "smart" AcuVid solution which reduces risk and adds a layer of quality control which currently doesn't exist with other rapid tests."

The Afero next-generation Intelligent Edge platform provides hardened security from devices to the cloud.

Ridge Global works with C-suite executives and corporate directors to reduce enterprise risk and to build more resilient organizations through innovative preparedness, protection, response and education capabilities.

Therma Bright is a progressive medical device technology company focused on providing consumers and medical professionals with quality medical devices that address their medical and healthcare needs.

Therma Bright Inc. (THRM) is unchanged, trading at C$0.44 per share at 11:30 am ET.

More From The Market Herald
HempFusion (TSX:CBD.U) announces US$2M private placement

" HempFusion (TSX:CBD.U) increases private placement

HempFusion Wellness (CBD.U) has increased the size of its previously announced non-brokered private placement to over US$2,500,000.
Neovasc’s (TSX:NVCN) Reducer receives first national European reimbursement

" Neovasc (TSX:NVCN) announces FDA approval of clinical trial

Neovasc (NVCN) has received approval from the FDA for the Investigational Device Exemption regarding its COSIRA-II IDE Clinical Trial.
Relay Medical (CSE:RELA) & Fio to provide rapid COVID-19 testing at TIFF

" ScreenPro (CSE:SCRN) providing COVID-19 testing at TIFF

ScreenPro (SCRN) is providing COVID-19 testing services at this year’s Toronto International Film Festival.
American Pacific Mining - President, Eric Saderholm. - The Market Herald Canada

" American Pacific Mining (CSE:USGD) reports bonanza-grade gold and silver

American Pacific (USGD) has doubled the size of its Tuscarora Property and reported bonanza-grade samples of gold and silver.